50 results about "Lipid binding" patented technology

Disclosed are infant formulas comprising fat, protein, carbohydrate, vitamins, and minerals, including on an as-fed basis, at least about 5 mg / L of gangliosides, at least about 150 mg / L of phospholipids, at least about 70 mg / L of total sialic acid with at least about 2.5% as lipid-bound sialic acid, at least about 0.13% docosahexaenoic acid by weight of total fatty acids, and at least about 0.25% arachidonic acid by weight of total fatty acids. Also disclosed are methods of accelerating brain development, neural migration, and cognitive development in an infant by administering the infant formulas during the first 2-4 months of life, preferably as a sole source of nutrition.

Provided by the present invention are formulations suitable for application to mammalian eyes which contain a lipid binding protein and a polar lipid, present as a soluble complex in an aqueous electrolyte. The formulations described have shear-thinning (non-Newtonian viscosity) and surface tension properties to natural tears and are therefore useful as artificial tear substitutes for the treatment of dry eyes (e.g. keratoconjunctivitis sicca) and useful in ophthalmic applications in general.

Techniques, methods and lavages are disclosed for prevention or treatment of shock, particularly cecal ligation or cecal inoculation shock, by administering a specific therapeutic agent, which is able to use smaller volumes of reagent to achieve partial to complete inhibition, than other previously described techniques. The agent includes a combination of enzyme inhibitor, cytotoxic lipid binding protein, and antibiotic.

The current invention provides polypeptides and polypeptide conjugates that include an exogenous N-linked glycosylation sequence. The N-linked glycosylation sequence is preferably a substrate for an oligosaccharyltransferase (e.g., bacterial PgIB), which can catalyze the transfer of a glycosyl moiety from a lipid-bound glycosyl donor molecule (e.g., a lipid-pyrophosphate-linked glycosyl moiety) to an asparagine (N) residue of the glycosylation sequence. In one example, the asparagine residue is part of an exogenous N-linked glycosylation sequence of the invention. The invention further provides methods of making the polypeptide conjugates that include contacting a polypeptide having an N-linked glycosylation sequence of the invention and a lipid-pyrophosphate-linked glycosyl moiety (or phospholipid-linked glycosyl moiety) in the presence of an oligosaccharyltransferase under conditions sufficient for the enzyme to transfer the glycosyl moiety to an asparagine residue of the N-linked glycosylation sequence. Exemplary glycosyl moieties that can be conjugated to the glycosylation sequence include GlcNAc, GlcNH, bacillosamine, 6-hydroybacillosamine, GalNAc, GaINH, GlcNAc-GlcNAc, GlcNAc-GlcNH, GlcNAc-Gal, GlcNAc-GlcNAc-Gal-Sia, GlcNAc-Gal-Sia, GlcNAc-GlcNAc-Man, and GlcNAc-GlcNAc-Man(Man)2. The transferred glycosyl moiety is optionally modified with a modifying group, such as a polymer (e.g., PEG). In one example, the modified glycosyl moiety is a GIcNAc or a sialic acid moiety.

The present disclosure provides detection methods employing HCV core lipid binding domain and DNA binding domain monoclonal antibodies or antibody fragments. In certain embodiments, the lipid binding domain monoclonal antibody or antibody fragment recognizes an epitope in amino acids 141 to 161 of HCV core protein and the DNA binding domain antibody or antibody fragment recognizes an epitope in amino acids 95-123 (e.g., in amino acids 99-117) of HCV core protein.

The invention relates to an irinotecan nano lipid binding preparation and a preparation method thereof. The irinotecan nano lipid binding preparation contains phospholipid, polyethylene glycol-dodecahydroxycy stearate, glycerol, ethanol and irinotecan, as well as an aqueous solvent for injection. The irinotecan nano lipid binding preparation is even in grain size, and as the lipid binding preparation, capable of reducing the toxicity of the irinotecan with long circulation effect and enhancing the tumor targeted enrichment effect and improving the compliance of a patient, and the preparation method is simple in process, high in repeatability and applicable to industrial production.

The invention provides compositions and methods for delivery of a bioactive agent to an individual. Delivery vehicles are provided that include a bioactive agent in disc shaped particles that include one or more lipid binding polypeptides circumscribing the perimeter of a lipid bilayer in which the bioactive agent is localized. Chimeric lipid binding polypeptides are also provided and may be used to add additional functional properties to the delivery particles.

Provided herein are compositions and methods for delivery of nucleic acids to individuals and to cells, including nucleic acid delivery particles that comprising a lipid-binding polypeptide, a lipid bilayer comprising one or more cationic lipids, and a nucleic acid.

A method of measuring Reelin as a biomarker, to non-destructively assess or predict DHA levels in the brain and in other, currently inaccessible or difficult-to-access, key components of the central nervous system (CNS) is described. Also described is a method to prevent, delay the onset of, or treat Reelin deficiency or dysfunction and / or a disease or condition associated with Reelin deficiency or dysfunction, comprising administering to a patient diagnosed with or suspected of having a Reelin deficiency or dysfunction an amount of a PUFA, and particularly an omega-3 PUFA, and more particularly, docosahexaenoic acid (DHA) or a precursor or source thereof, to compensate for the effects of Reelin deficiency or dysfunction in the patient. Also described is a method to prevent or reduce development defects or disorders associated with Reelin dysfunction or deficiency through the supplemental use of polyunsaturated fatty acids (PUFAs- unsaturated fatty acids having two or more double bonds), and particularly highly unsaturated fatty acids (HUFAs- unsaturated fatty acids having three or more double bonds), and more particularly a HUFA selected from arachidonic acid (ARA), eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and docosapentaenoic acid (DPA), and even more particularly omega-3 HUFAs, and more particularly DHA, to: compensate for reduced fatty acid binding protein or function thereof in the patient; compensate for reduced brain lipid binding protein or function thereof in the patient; improve the activity of fatty acid binding proteins in the patient.

The invention provides compositions and methods for delivery of a bioactive agent to an individual. Delivery vehicles are provided that include a bioactive agent in disc shaped particles that include one or more lipid binding polypeptides circumscribing the perimeter of a lipid bilayer in which the bioactive agent is localized. Chimeric lipid binding polypeptides are also provided and may be used to add additional functional properties to the delivery particles.

Provided herein are fluorescent lipid binding proteins (FLBPs). The FLBPs comprise a lipid binding domain linked to a fluorophore, whrereby the fluorophore's fluorescence emission undergoes a spectral change upon lipid binding. the fluorophore is selected from the group consisting of 2-dimethylamino-6-acyl-naphthalene (DAN) and RED fluorophore and the lipid binding protein is selected from the group consisting of ENTH domain of epsin 1, C2 domain of bovine lactadherin, C 1B domain of protein kinase C-gamma, C2 domain of cytosolic phospholipase A2-beta, and PH domain of Bruton's tyrosine kinase PH.

The invention provides a nanoscale particle comprising a lipid binding polypeptide, lipids and a hydrophobic agent, wherein the hydrophobic agent is different from the lipids, and wherein the lipid binding polypeptide is a saposin-like protein or a derivative or truncated form thereof. The invention further provides a process for preparing a particle comprising a saposin-like protein or a derivative or truncated form thereof and lipids comprising the step of (a) contacting the saposin-like protein or a derivative or truncated form thereof with solubilized lipids in a liquid environment and (b) allowing for the self-assembly of the particle at a pH of from 5.0 to 10.0. In addition, the invention provides a pharmaceutical composition comprising the particle of the invention for delivering a hydrophobic agent to an individual in need thereof and includes the use of the particle of the invention in preventing, treating or lessening the severity of a disease or its use in a diagnostic method, a cosmetic treatment, as hydrophobic agent delivery particle, as a tool for drug development, drug screening, membrane protein research or as vaccination formulation.

The present invention solves the three-dimensional structure of BPI and thereby provides atomic coordinates of BPI from the analysis of x-ray diffraction patterns of sufficiently high resolution for three-dimensional structure determination of the protein, as well as methods for rational drug design, based on using amino acid sequence data and / or x-ray diffraction data provided on computer readable media, as analyzed on a computer system having suitable computer algorithms; and atomic coordinates are provided yielding structural information on related proteins, including the lipid binding and lipid transport protein family that includes BPI, LBP, CETP and PLTP.

Disclosed herein are compositions and methods used for detecting and measuring ligands for nuclear receptors and intracellular lipid binding proteins in both in vitro and in vivo samples.

The invention refers to a method for producing an antigen comprising at least one hydrophobic or partially hydrophobic antigen molecule from a virus, a bacterium, fungus, protozoan, parasite, a human neoplastic cell or an animal neoplastic, tumor or 5 cancer cell, the method comprising the steps of providing a virus, or cell comprising an antigen molecule, purifying the cell comprising the antigen molecule, solubilizing the antigen molecule in a solubilizing agent that preserves an intact antigen molecule upon solubilization and reconstituting the antigen molecule in a lipid-binding polypeptide that provides a lipid membrane mimicking environment and a reconstituted antigen particle 10 obtained by this method.

A method for detection or monitoring status of traumatic brain injury (TBI) or spinal cord injury (SCI) in a subject is provided. In one embodiment, the method comprises contacting a specimen of bodily fluid obtained from the subject with reagents for assaying for a marker of TBI selected from aldolase C (ALDOC) and brain lipid binding protein (BLBP), or a trauma-specific break down product (BDP) of ALDOC or BLBP. The method further comprises measuring the amount of marker present in the specimen as compared to a control sample, and determining the presence of TBI or SCI when an elevated amount of marker is present in the specimen compared to the control sample. The method can comprises measuring the amount of glutamine synthetase (GS), astrocytic phosphoprotein PEA-15 (PEA15), αB-crystallin (CRYAB / HSP27), a cleavage product of ALDOC, GS, PEA15, or CRYAB, or a combination of two or more thereof.